Vertex Pharmaceuticals Incorporated
US ˙ NasdaqGS ˙ US92532F1003

SecurityVRTX / Vertex Pharmaceuticals Incorporated
InstitutionNikko Asset Management Americas, Inc.
Latest Disclosed Ownership2,115 shares
Latest Disclosed Value $ 944,263
Nikko Asset Management Americas, Inc. reports 66.50% decrease in ownership of VRTX / Vertex Pharmaceuticals Incorporated

On May 7, 2026 - Nikko Asset Management Americas, Inc. filed a 13F-HR form disclosing ownership of 2,115 shares of Vertex Pharmaceuticals Incorporated (US:VRTX) valued at $944,432 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 11, 2026 disclosing 6,314 shares of Vertex Pharmaceuticals Incorporated. This represents a change in shares of -66.50% during the quarter. The current value of the position is $945,045 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-07 2026-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 2,115 -4,199 -66.50 944 -67.02 0.0134
2026-02-11 2025-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 6,314 -588 -8.52 2,862 5.92 0.0331
2025-11-12 2025-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 6,902 375 5.75 2,702 -6.96 0.0262
2025-08-11 2025-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 6,527 -145 -2.17 2,905 -10.18 0.0290
2025-05-07 2025-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 6,672 -707 -9.58 3,234 8.82 0.0417
2025-02-10 2024-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 7,379 -1,092 -12.89 2,972 -24.56 0.0322
2024-11-07 2024-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 8,471 -3,349 -28.33 3,938 -28.89 0.0446
2024-08-09 2024-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 11,820 -3,212 -21.37 5,538 -11.83 0.0639
2024-05-02 2024-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 15,032 -2,507 -14.29 6,282 -11.98 0.0624
2024-02-08 2023-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 17,539 -1,233 -6.57 7,136 9.33 0.0686
2023-11-09 2023-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 18,772 -143 -0.76 6,528 -1.89 0.0780
2023-08-14 2023-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 18,915 651 3.56 6,653 17.92 0.0700
2023-05-03 2023-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 18,264 -1,389 -7.07 5,643 -0.51 0.0650
2023-02-13 2022-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 19,653 -4,951 -20.12 5,672 -19.91 0.0817
2022-11-14 2022-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 24,604 -24,981 -50.38 7,081 -48.11 0.0904
2022-08-04 2022-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 49,585 -31,950 -39.19 13,646 -36.14 0.1685
2022-05-06 2022-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 81,535 -32,454 -28.47 21,370 -14.08 0.1569
2022-02-08 2021-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 113,989 -13,207 -10.38 24,872 7.80 0.1308
2021-11-09 2021-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 127,196 19,115 17.69 23,073 6.47 0.0991
2021-08-09 2021-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 108,081 -15,166 -12.31 21,670 -18.18 0.0848
2021-05-03 2021-03-31 13F Vertex Pharmaceuticals COM 92532F100 123,247 33,798 37.78 26,485 25.28 0.1297
2021-02-11 2020-12-31 13F Vertex Pharmaceuticals COM 92532F100 89,449 5,457 6.50 21,140 -6.23 0.1201
2020-11-02 2020-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 83,992 21,429 34.25 22,544 27.10 0.1998
2020-08-07 2020-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 62,563 -47,860 -43.34 17,737 -32.49 0.2324
2020-05-04 2020-03-31 13F/A-1 Vertex Pharmaceuticals COM 92532F100 110,423 -12,467 -10.14 26,275 -2.35 0.4880
2020-04-30 2020-03-31 13F Vertex Pharmaceuticals COM 92532F100 110,423 -12,467 26,275 497,829.8220
2020-02-06 2019-12-31 13F Vertex Pharmaceuticals COM 92532F100 122,890 -3,264 -2.59 26,907 25.89 0.4237
2019-10-29 2019-09-30 13F Vertex Pharmaceuticals COM 92532F100 126,154 20,594 19.51 21,373 10.41 0.3797
2019-07-29 2019-06-30 13F Vertex Pharmaceuticals COM 92532F100 105,560 62,110 142.95 19,358 142.19 0.3797
2019-04-30 2019-03-31 13F Vertex Pharmaceuticals COM 92532F100 43,450 43,450 7,993 0.2108
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.